Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Receivables - Other (2016 - 2025)

Historic Receivables - Other for OptimizeRx (OPRX) over the last 10 years, with Q3 2025 value amounting to $3.7 million.

  • OptimizeRx's Receivables - Other fell 3798.73% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 3798.73%. This contributed to the annual value of $3.2 million for FY2024, which is 4666.78% down from last year.
  • As of Q3 2025, OptimizeRx's Receivables - Other stood at $3.7 million, which was down 3798.73% from $3.5 million recorded in Q2 2025.
  • Over the past 5 years, OptimizeRx's Receivables - Other peaked at $6.1 million during Q4 2023, and registered a low of $2.1 million during Q4 2021.
  • Moreover, its 5-year median value for Receivables - Other was $3.7 million (2022), whereas its average is $4.1 million.
  • Per our database at Business Quant, OptimizeRx's Receivables - Other skyrocketed by 17876.58% in 2021 and then crashed by 4666.78% in 2024.
  • Quarter analysis of 5 years shows OptimizeRx's Receivables - Other stood at $2.1 million in 2021, then soared by 69.73% to $3.6 million in 2022, then surged by 69.62% to $6.1 million in 2023, then tumbled by 46.67% to $3.2 million in 2024, then rose by 14.84% to $3.7 million in 2025.
  • Its Receivables - Other stands at $3.7 million for Q3 2025, versus $3.5 million for Q2 2025 and $4.2 million for Q1 2025.